Short Interest in Janux Therapeutics, Inc. (NASDAQ:JANX) Rises By 19.8%

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 7,680,000 shares, a growth of 19.8% from the December 31st total of 6,410,000 shares. Approximately 16.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,050,000 shares, the days-to-cover ratio is presently 7.3 days.

Insider Transactions at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the sale, the insider now owns 82,139 shares of the company's stock, valued at approximately $3,473,658.31. The trade was a 3.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David Alan Campbell sold 15,000 shares of Janux Therapeutics stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total value of $1,005,000.00. Following the completion of the sale, the chief executive officer now owns 242,054 shares in the company, valued at $16,217,618. This represents a 5.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 86,668 shares of company stock valued at $4,872,515 over the last 90 days. 29.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Janux Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP raised its position in shares of Janux Therapeutics by 54.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 24,019 shares of the company's stock worth $1,005,000 after purchasing an additional 8,422 shares during the last quarter. AQR Capital Management LLC purchased a new position in Janux Therapeutics during the second quarter worth $215,000. The Manufacturers Life Insurance Company raised its holdings in shares of Janux Therapeutics by 234.7% in the second quarter. The Manufacturers Life Insurance Company now owns 24,048 shares of the company's stock worth $1,007,000 after acquiring an additional 16,864 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock valued at $87,000 after acquiring an additional 339 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Janux Therapeutics by 639.5% during the third quarter. Nisa Investment Advisors LLC now owns 20,343 shares of the company's stock valued at $924,000 after acquiring an additional 17,592 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on JANX shares. HC Wainwright increased their price target on Janux Therapeutics from $63.00 to $70.00 and gave the company a "buy" rating in a research report on Tuesday, December 3rd. Lifesci Capital raised shares of Janux Therapeutics to a "strong-buy" rating in a report on Friday, December 27th. Cantor Fitzgerald reiterated an "overweight" rating and set a $200.00 price target on shares of Janux Therapeutics in a report on Wednesday, December 11th. Leerink Partnrs upgraded shares of Janux Therapeutics to a "strong-buy" rating in a report on Friday, November 22nd. Finally, UBS Group began coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They set a "buy" rating and a $69.00 price objective for the company. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $89.90.

Janux Therapeutics Stock Up 8.1 %

NASDAQ JANX traded up $3.34 during trading hours on Wednesday, hitting $44.65. 998,105 shares of the stock were exchanged, compared to its average volume of 1,131,452. Janux Therapeutics has a 12-month low of $7.81 and a 12-month high of $71.71. The stock has a 50-day moving average of $51.33 and a 200 day moving average of $48.42. The company has a market cap of $2.34 billion, a price-to-earnings ratio of -38.16 and a beta of 3.16.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The firm's revenue was down 82.6% on a year-over-year basis. On average, equities research analysts expect that Janux Therapeutics will post -1.38 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.